You are here:
Over the next four years, Helmholtz Munich participates in a European research consortium, aiming to develop an innovative technology that could boost the regeneration of neurons in diseases that currently have limited therapeutic options. The…
Researchers created a new approach to reduce the complexity of the NMR experiments and facilitate the investigation of membrane protein systems of pharmaceutical importance.
A team led by Helmholtz Munich scientist Dr. Grzegorz Popowicz unveils the Molecular Interactions Structurally Optimized (MISATO) dataset, offering a transformative approach to training AI models for designing new drug molecules. MISATO represents a…
A team of Helmholtz Munich scientists has made a significant advancement in the understanding of ferroptosis, a complex form of cell death, by successfully detecting it retrospectively in human pathological conditions. This pioneering research,…
In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…
The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 are powerful but inefficient in the cytoplasm of cells, where many RNA viruses replicate. Scientists from Helmholtz Munich…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
